Photocure Investor Hub
A commercial-stage company focused on bladder cancer
Hexvix®/Cysview® is a product for the detection of bladder cancer:
- Established position as an innovation leader in the large and underserved bladder cancer treatment market.
- Treatment guidelines and reimbursement supports market penetration.
- In excess of USD 40M in global market sales.
- Specialist salesforce established in the U.S. and Europe with additional potential value in other territories through our partners; Genotests (Chile), Endotherapeutics Group (Australia/New Zealand), and Asieris MediTech Co., Ltd. (China).
- Large untapped potential for Hexvix®/Cysview® in existing and new market segments/territories.
- Opportunities following the FDA approval of Cysview® for use with flexible cystoscope.
- Exploring expansion of bladder cancer portfolio to leverage commercial infrastructure.
21st Annual Needham Healthcare Conference11 Apr 2022 - 14 Apr 2022https://wsw.com/webcast/needham117/pho.ol/2531984
American Urological Association's 2022 Annual Meeting (AUA)13 May 2022 - 16 May 2022https://www.auanet.org/annualmeeting
European Association of Urology: Annual EAU Congress1 Jul 2022 - 4 Jul 2022https://eaucongress.uroweb.org/
Photocure ASA is followed by the analysts listed below. Please note that any opinions, estimates or forecasts regarding Photocure ASA's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Photocure ASA or its management.
Photocure ASA does not by its reference below or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
ABG Sundal Collier
Tel: +46 8 566 286 03
Tel: +46 733 26 37 69
Tel: +46 8 701 1995
Norne Securities AS
Tel: +47 21 95 37 49